This week, Proscia, a Philadelphia-based digital pathology company started by entrepreneurs from Johns Hopkins University and the University of Pittsburgh, announced the completion of an $8.3 million Series A financing led by Flybridge Capital Partners. Other participants in the round included Emerald Development Managers, Fusion Fund, Razor’s Edge Ventures, and RobinHood Ventures.
The last time Medgadget heard from the company, it had added new cancer image analysis tools to the Proscia Pathology Cloud. The new funds will be used to continue expanding Proscia’s current digital pathology software, fuel development and commercialization of new artificial intelligence (AI)-enabled workflows targeting high-volume, high-impact cancers, and ramp up sales and marketing efforts. The first AI-enabled module on the company’s platform, DermAI, is slated for release this coming December.
On the move towards AI-based tools, Proscia CEO David West commented that, “Digital pathology and artificial intelligence are unlocking new possibilities for pathologists in the fight against cancer. Pathology has been historically underserved by technology, and we believe that powerful software tools will push the boundaries of how modern pathology is practiced.”
As noted in the press release, Proscia’s technology is currently used by thousands of pathologists, scientists, histotechnicians, and lab managers at more than 300 clinical and research facilities worldwide. The cloud-based, modular platform easily integrates with existing technology ecosystems and allows clients to:
- Adopt digital pathology on own terms by rolling out new features and capabilities seamlessly
- Create new image-based workflows to streamline operations, reduce turnaround times, cut costs
- Open up new imaging and analytics revenue streams to differentiate themselves from peers
- Protect and future-proof current investments in hardware and other infrastructure
- Improve diagnostic efficiency and quality to improve patient outcomes